Drug intelligence / Profile preview

mometasone furoate + tazarotene

Development stage: Unknown
Modality: Small Molecules
Administration: Topical

Overview

Mometasone furoate + tazarotene is a combination medication used primarily for the treatment of plaque psoriasis. Tazarotene is a third-generation topical retinoid that slows down skin cell turnover and decreases inflammation, while mometasone furoate is a synthetic corticosteroid that blocks inflammatory chemical messengers. This combination provides enhanced efficacy compared to either agent alone, with improved tolerability and longer periods of remission after treatment discontinuation.

Other names: tazarotene + mometasonetazarotene+mometasonemometasone furoate + tazarotene

Targets

GR (Glucocorticoid receptor)RARG (Retinoic acid receptor gamma)RARB (Retinoic acid receptor beta)

Beyond the preview

Go deeper on mometasone furoate + tazarotene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mometasone furoate + tazarotene.

Explore the full profile